Non Hodgkin Lymphoma
Conditions
Interventions
Case series:Three days after cyclophosphamide and fludarabine chemotherapy, patients were treated with a dose of 1-10 x 106 CART positive T cells per kg body weight
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Pathologic immunohistochemical or flow cytological examination confirmed CD19/CD20/CD22/CD30 positive malignant lymphoma; Previously received at least two lines of standard chemotherapy; Aged from 16 to 65 years; Estimated time of survival more than 3 months; ECOG=2; Vital organs function normally: cardiac ejection fraction =50%, normal ECG,CCr=40ml/min, ALT and AST =3 ULN, TBIL =2mg/dl, HGB =80g/L, Hgb=80g/L, ANC=1×109/L, PLT=50×109/L;Women of childbearing age with a negative pregnancy test; use contraception; with measurable lesions; Give signed informed consent before enrollment.
Exclusion criteria
Exclusion criteria: Used immunosuppressive drugs or glucocorticoids within 1 week before enrollment; Active infection; HIV test positive; Active hepatitis b or c infection; Pregnant or lactating women; Previous or combined history of other malignancies, not included: patients with cured basal or squamous cell carcinoma and in situ carcinoma of the cervix; participate in other clinical trials; Congenital immune deficiency; History of myocardial infarction and severe arrhythmia within 6 months; Uncontrolled hypertension, coronary heart disease, stroke, cirrhosis, nephritis and other serious complications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| complete response rate;Time to treatment failure;Progression-free survival time;overall survival;time to response;safety; | — |
Countries
China
Contacts
Public ContactTongyu LIN
Sun Yat-sen University Cancer Center
Outcome results
None listed